Drugs / Eplerenone
Eplerenone
also known as
Inspra · EPL · Eplerenone (Generic) · Eplerenone or INSPRA · Eraloner · Eraloner (Eplerenone 50 mg)
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | INSPRA | — | 2003-10-07 – 2008-01-31 | fda.gov ↗ |
| Approved | US (FDA) | INSPRA | — | 2002-09-27 | fda.gov ↗ |
Trials 75 · started per year
today
US approved 2002
1
3
3
1
3
3
1
6
2
3
7
6
3
4
3
3
2
1
5
5
2
3
4
1
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07345845 | Dec 2025 → Feb 2028 expected | preeclampsia | Anna Stanhewicz, PhD | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06749418 | Jan 2025 → Jan 2027 expected | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT03923530 | Jun 2019 → Feb 2020 | aortic valve stenosis, diastolic heart failure, hypertensive disorder | North Florida Foundation for Research and Education | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT07795762 | Oct 2026 → Feb 2027 expected | ocular hypertension | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06831864 | Feb → May 2025 | symptomatic heart failure | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT06556732 | Aug 2024 overdue | atrial fibrillation | Assiut University | Recruiting | No outcome recorded |
| Phase 1 | NCT03165240 | Oct 2017 → Apr 2020 | diabetic kidney disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02957435 | Jul → Dec 2017 | — | Biolab Sanus Farmaceutica | Withdrawn | No outcome recorded |
| Phase 1 | NCT02607657 | May → Oct 2016 | — | Biolab Sanus Farmaceutica | Withdrawn | No outcome recorded |
| Phase 1 | NCT02532998 | Sep → Dec 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01473108 | Mar → Nov 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00990223 | Oct → Nov 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865176 | Jun → Jul 2006 | hypertensive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00865618 | Jun → Jul 2006 | hypertensive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01146197 | Feb 2010 → Dec 2012 | Gitelman syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 29 trials · 1 missed | ||||||
| Phase 2 | NCT07029503 | Feb 2026 → Feb 2027 expected | chronic kidney disease, systolic heart failure | Karolinska Institutet | Recruiting | No outcome recorded |
| Phase 2 | NCT05198791 | Feb 2022 → Jul 2026 overdue | acute myocardial infarction | NHS National Waiting Times Centre Board | Recruiting | No outcome recorded |
| Phase 2 | NCT04300881 | Oct 2019 → Jan 2021 | retinal edema, vitreous detachment | Wagner Macula & Retina Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02629094 | Dec 2015 → Sep 2017 | fatty liver disease, triglyceride deposit cardiomyovasculopathy | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Missed primary |
| Phase 2 | NCT02153125 | Apr 2014 → Jun 2015 | central serous chorioretinopathy | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01822561 | May 2013 → Apr 2017 | central serous chorioretinopathy | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01834768 | Feb → Apr 2013 | chronic kidney disease | Reims University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01801228 | Feb 2013 → Oct 2015 | cirrhosis of liver | Emma Nilsson | Withdrawn | No outcome recorded |
| Phase 2 | NCT00649311 | Apr → Sep 2003 | hypertensive disorder | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT02525796 | Jan 2016 → Oct 2021 | primary hyperparathyroidism | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 2/3 | NCT02215330 | Oct 2014 → Mar 2017 | central serous chorioretinopathy | Prim. Prof. Dr. Oliver Findl, MBA | Unknown | No outcome recorded |
| Phase 2/3 | NCT01708798 | May 2014 → Nov 2016 | breast cancer | University of British Columbia | Terminated | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07828223 | Feb 2027 → Dec 2030 expected | — | Central Hospital, Nancy, France | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07569640 | Aug 2026 → Apr 2029 expected | symptomatic heart failure | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT02490904 | Oct 2016 → Nov 2021 overdue | end stage renal failure | Central Hospital, Nancy, France | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01586442 | Mar 2012 → Mar 2015 | glucose intolerance, heart failure, type 2 diabetes mellitus | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT01319344 | Sep 2010 → Dec 2012 | metabolic syndrome X | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01115855 | Jul 2010 → Sep 2015 | heart failure | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00147615 | Oct 2004 → Jun 2006 | hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00147589 | Sep 2004 → Jan 2007 | hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 428 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07513883 | Mar 2026 → Sep 2028 expected | heart failure | Ziekenhuis Oost-Limburg | Recruiting | No outcome recorded |
| Phase 4 | NCT06168994 | Feb 2024 → Sep 2026 overdue | paroxysmal atrial fibrillation | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT03418649 | Jun 2023 → Dec 2025 | intervertebral disk degenerative disorder, radiculopathy | University of Cincinnati | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05688579 | Apr 2023 → Dec 2026 expected | hyperaldosteronism, hypertensive disorder | Nanfang Li | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04746495 | Feb → Jul 2023 | essential hypertension | University of Michigan | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05030545 | Dec 2022 → Oct 2026 expected | hypertensive disorder, primary aldosteronism | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05129722 | Oct 2022 → May 2024 | diastolic heart failure | The George Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04840342 | Feb 2022 → Sep 2025 | apparent mineralocorticoid excess, essential hypertension | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04697485 | Jan 2021 → Jan 2022 | diabetes mellitus, heart failure | Northwestern University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04519164 | Dec 2020 → Sep 2025 | hypertensive disorder, metabolic syndrome X | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04142788 | Aug 2020 → Dec 2022 | congestive heart failure | NHS Greater Glasgow and Clyde | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03683069 | Jan 2019 → Aug 2023 | essential hypertension, genetic | Brigham and Women's Hospital | Completed | Mixed |
| Phase 4 | NCT02345590 | May 2015 → Dec 2018 | abdominal aortic aneurysm | Bayside Health | Unknown | No outcome recorded |
| Phase 4 | NCT03186742 | Jul 2014 → Jan 2017 | essential hypertension, hypertensive heart disease, obstructive sleep apnea syndrome | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02462499 | Jun 2014 → Sep 2016 | central serous chorioretinopathy | Semmelweis University | Completed | No outcome recorded |
| Phase 4 | NCT01794091 | Aug 2013 → Aug 2017 | type 2 diabetes mellitus | Brigham and Women's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01971593 | Aug 2013 → Mar 2016 | tetralogy of fallot, transposition of the great arteries, univentricular heart | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01837108 | Apr → Dec 2013 | — | Radboud University Medical Center | Completed | Missed primary |
| Phase 4 | NCT01302236 | Mar 2011 → Jul 2012 | chronic kidney disease, hypertensive disorder | Jichi Medical University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01176968 | Sep 2010 → Oct 2012 | myocardial infarction | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00401856 | Dec 2007 → Apr 2013 | cardiomyopathy | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00553722 | Nov 2007 → Nov 2009 | hyperaldosteronism, hypertensive disorder | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00515021 | Apr 2007 → Apr 2010 | metabolic syndrome X | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00132093 | Apr 2005 → ? | acute myocardial infarction | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 4 | NCT00082589 | Apr 2004 → Mar 2006 | congestive heart failure | Viatris Inc. | Completed | Missed primary |
| Phase 4 | NCT00147563 | Oct 2003 → May 2006 | essential hypertension | Pfizer | Completed | No outcome recorded |
| Phase not applicable11 trials · 1 met primary · 1 missed | ||||||
| — | NCT06091475 | Dec 2023 → Aug 2026 overdue | dilated cardiomyopathy, heart failure | Imperial College London | Recruiting | No outcome recorded |
| — | NCT02740179 | Jan 2017 → Mar 2022 | HIV infectious disease | Massachusetts General Hospital | Completed | Mixed |
| — | NCT03017703 | Dec 2016 → Oct 2019 | — | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT02118753 | Mar 2014 → Dec 2015 | ischemic disease | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01650012 | Mar → Dec 2013 | end stage renal failure | McMaster University | Completed | No outcome recorded |
| — | NCT01832558 | Nov 2012 → Dec 2020 | chronic kidney disease | Medical University of Vienna | Unknown | No outcome recorded |
| — | NCT01405456 | Jan 2012 → May 2017 | HIV infectious disease | Massachusetts General Hospital | Completed | Missed primary |
| — | NCT01394627 | Jan 2011 → Aug 2016 | hypoglycemia | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01786551 | Mar 2010 → Jan 2013 | autoinflammatory syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00505336 | Apr 2006 → Jul 2008 | diastolic heart failure | St Vincent's University Hospital, Ireland | Completed | No outcome recorded |
| — | NCT00214825 | Aug 2003 → Mar 2006 | diabetes mellitus, proteinuria | Brigham and Women's Hospital | Completed | Met primary |
| Comparator or background therapy47 trials | ||||||
| Phase 1 | NCT06649409 Comparator | Jun 2024 | — | Santhera Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02871648 Comparator | Jan 2016 → Oct 2019 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01237899 Comparator | Oct 2010 → Jan 2011 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT07238400 Comparator | Mar 2026 → Mar 2029 expected | hypertensive disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04143412 Comparator | Feb 2019 → Feb 2020 | diabetic kidney disease | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2 | NCT02345044 Comparator | Jan → Aug 2015 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01955694 Comparator | Nov 2013 → Jan 2015 | heart failure | Bayer | Completed | Missed primary |
| Phase 2 | NCT01996449 Comparator | Jul 2013 → Apr 2021 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01807221 Comparator | Jun 2013 → Nov 2014 | heart failure | Bayer | Completed | Missed primary |
| Phase 2 | NCT01427972 Comparator | Sep 2011 → Mar 2013 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01373086 Comparator | May → Oct 2011 | hypertensive disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00817635 Comparator | Dec 2008 → Oct 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00758524 Comparator | Sep 2008 → Jul 2009 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00647192 Comparator | Mar 2008 → Feb 2012 | atrial fibrillation | University Hospital, Saarland | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00315016 Comparator | Jan 2007 → Jul 2011 | diabetic kidney disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04450953 Comparator | Oct 2021 → Nov 2025 overdue | — | Central Hospital, Nancy, France | Recruiting | No outcome recorded |
| Phase 3 | NCT02890173 Comparator | Sep 2016 → Jul 2017 | essential hypertension | Daiichi Sankyo | Completed | Met primary |
| Phase 3 | NCT02354352 Comparator | Mar 2015 → May 2018 | Duchenne muscular dystrophy | Ohio State University | Completed | No outcome recorded |
| Phase 3 | NCT01857856 Comparator | May 2013 → Oct 2021 | familial dilated cardiomyopathy | M.p. van den Berg, MD, PhD, professor in Cardiology | Completed | No outcome recorded |
| Phase 3 | NCT01100203 Comparator | Apr 2010 → Jan 2012 | chronic kidney disease | Lene Boesby | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00138944 Comparator | Jan 2007 → May 2008 | essential hypertension | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00232180 Comparator | Mar 2006 → May 2010 | heart failure | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05593055 Comparator | Aug 2023 → Apr 2027 expected | hypertensive disorder | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03984591 Comparator | Nov 2020 → Dec 2028 expected | systolic heart failure | Bispebjerg Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04575675 Background | May → Nov 2020 | heart failure, hypotensive disorder | Cheng-Hsin General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03476616 Comparator | Sep 2018 → Jun 2025 | essential hypertension, obesity disorder | Hippocration General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03079141 Comparator | Feb 2017 → Aug 2019 | central serous chorioretinopathy | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02809963 Comparator | Nov 2015 → Nov 2017 | type 2 diabetes mellitus | Herlev Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02200822 Comparator | Jul 2014 → Feb 2019 | heart failure | Hasselt University | Completed | No outcome recorded |
| Phase 4 | NCT01887119 Comparator | Oct 2013 → Nov 2018 | abdominal obesity-metabolic syndrome, hypertensive disorder | Maastricht University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01893788 Comparator | Apr 2013 → Mar 2016 | hypertensive heart disease | Nagoya University | Unknown | No outcome recorded |
| Phase 4 | NCT01275352 Comparator | Dec 2011 → Dec 2014 | hypertensive disorder | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00703352 Comparator | Jul 2008 → Dec 2010 | transposition of the great arteries | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00430924 Comparator | Mar 2007 → Aug 2009 | chronic kidney disease | Lene Boesby | Completed | No outcome recorded |
| Phase 4 | NCT00391846 Background | Oct 2006 → Jan 2009 | left ventricular failure | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00608465 Comparator | May 2006 → May 2009 | metabolic syndrome X | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00108251 Comparator | Aug 2004 → Sep 2007 | diastolic heart failure | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00187889 Comparator | Aug 2004 → Feb 2009 | myocardial ischemia | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00293150 Comparator | Sep 2003 → Sep 2007 | diastolic heart failure | The Cleveland Clinic | Terminated | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06208072 Comparator | Sep 2023 → Dec 2024 | essential hypertension, obesity disorder | Hippocration General Hospital | Unknown | No outcome recorded |
| — | NCT05797558 Comparator | Apr 2023 → May 2028 expected | aldosterone-producing adrenal cortex adenoma | Göteborg University | Recruiting | No outcome recorded |
| — | NCT01990677 Comparator | Oct 2013 → Mar 2015 | central serous chorioretinopathy | Wills Eye | Completed | No outcome recorded |
| — | NCT01521546 Comparator | Feb 2012 → Jun 2016 | Duchenne muscular dystrophy | Ohio State University | Completed | No outcome recorded |
| — | NCT00825188 Comparator | Jan 2009 → Mar 2014 | hypertensive disorder, obesity disorder | University of Mississippi Medical Center | Terminated | No outcome recorded Stop: Business |
| — | NCT00980031 Comparator | Apr 2007 → Sep 2011 | — | Creighton University | Terminated | No outcome recorded Stop: Business |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 124 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eplerenone | “HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone...” NCT06831864 ↗121“One group was treated with mineralocorticoid receptor antagonists(MRAs) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in...” NCT05688579 ↗ “The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the...” NCT07569640 ↗ “Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable).” NCT04142788 ↗ “Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg” NCT05129722 ↗ “25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day.” NCT04143412 ↗ “MRA (Spironolactone, Eplerenone) will be introduced and up titrated in week 3 and 7 respectively.” NCT05637853 ↗ “MRA: spironolactone or eplerenone (at the maximally tolerated dose, according to the SmPC)” NCT07513883 ↗ “Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin” NCT06091475 ↗ “Mineralocorticoid receptor antagonist, including spironolactone or eplerenone” NCT04575675 ↗ “first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop” NCT02200822 ↗ |
| Known as | EPL | “The MRB eplerenone (EPL) has been shown to reduce new onset AF and recurrent AF in HF patients (7).” NCT06168994 ↗ |
| Known as | Eplerenone (Generic) | “Eplerenone (Generic)” NCT01822561 ↗ |
| Known as | Eplerenone or INSPRA | “Eplerenone or INSPRA” NCT00315016 ↗ |
| Known as | Eraloner | “25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day.” NCT04143412 ↗ |
| Known as | Eraloner (Eplerenone 50 mg) | “Eraloner (Eplerenone 50 mg)” NCT04143412 ↗ |
| Known as | Inspra | “We assessed the translatability of urinary sodium to potassium ratio (Na+/K+) and plasma aldosterone as biomarkers of MR antagonism using eplerenone (Inspra®), a commercially...” PMID 22017794 ↗ Oct 20117“Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.” NCT02462499 ↗ “The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks.” NCT01996449 ↗ “INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets” NCT01955694 ↗ “Eplerenone (inspra), Bumetanide (Burinex) and Empagliflozin (jardiance)” NCT05129722 ↗ “Eplerenone (Inspra®)” NCT01473108 ↗ “Inspra (eplerenone)” NCT01807221 ↗ “Inspra /Eplerenone” NCT02629094 ↗ |
| Action | Inhibit | “aldosterone antagonism with eplerenone” PMID 20299607 ↗ Mar 2010 |
| Route | Oral | “50mg oral route” NCT00401856 ↗ |